Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04273672 · ClinicalTrials.gov registry record
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
A clinical trial of Parkinson Disease and Speech, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- 58
- Enrollment target
- 1
- Study location
NCT04273672: Completed study of Parkinson Disease and Speech, sponsored by University of Massachusetts, Worcester.
NCT04273672 is a study of Parkinson Disease and Speech that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 58 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04273672, a study of Parkinson Disease and Speech, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.
Primary Outcome
Mild cognitive impairment classified by Movement Disorders Society Task Force Level II Critieria
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cognitive Battery
- BEHAVIORAL Voice, Speech and Language Analysis
- BEHAVIORAL Questionnaires and Clinical Assessments
- GENETIC DNA Analysis
Study Locations (1)
Massachusetts
- UMass Medical School/UMass Memorial Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2025-02-28 |
What the finished NCT04273672 record still lists
NCT04273672 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 4 interventions - of which Cognitive Battery is the first listed.
NCT04273672 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04273672 about?
NCT04273672 is a clinical study titled "Speech, Linguistic and Acoustic Markers in Parkinson's Disease". The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. T...
What is the current status of trial NCT04273672?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2020-01-13. Estimated completion is 2025-02-28.
What conditions does trial NCT04273672 study?
This clinical trial studies the following conditions: Parkinson Disease, Speech, Cognitive Impairment, Mild.
What interventions are being tested in trial NCT04273672?
The interventions under investigation include: Cognitive Battery (DIAGNOSTIC_TEST), Voice, Speech and Language Analysis (BEHAVIORAL), Questionnaires and Clinical Assessments (BEHAVIORAL), DNA Analysis (GENETIC).
Who is sponsoring clinical trial NCT04273672?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04273672 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04273672's enrollment target sits among peer trials
58 146th of 297 higher than 152 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI